Scholars@Duke
Jun Ren

Jun Ren

Visiting Scholar in the Comprehensive Cancer Center
Duke Cancer Institute
jun.ren@duke.edu
Box 2606 Med Ctr, Durham, NC 27710
203 Research Drive Room 433, Box 2606, Durham, NC 27710

Overview

Jun Ren MD, PhD  joined Duke University as faculty from 2008. He has actively worked with Professor Kim Lyerly to create the global cancer programs featured on education and research on  cancer immunotherapy and cancer vaccines program. They have been keeping pursuing to set up the win-to-win platform thought overcoming these differences and difficulties between US and China since 2008. He and Kim Lyerly secured the transitional research for cancer immunotherapy and achieved clinical research success and expand the global academic prospectives  of Duke University.

Current Appointments & Affiliations

Visiting Scholar in the Comprehensive Cancer Center · 2008 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications

Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy.

Journal Article Infect Agent Cancer · April 9, 2025 BACKGROUND: The concurrent presence of COVID-19 infection in advanced cancer patients has increased the mortality since the compromised immunity was inevitably worsen. The role and clinical impact of autologous adoptive T cell immunotherapy (ACT) designed ... Full text Link to item Cite

Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation.

Journal Article Int J Radiat Oncol Biol Phys · October 1, 2021 PURPOSE: Radiation therapy (RT) modulates immune cells and cytokines, resulting in both clinically beneficial and detrimental effects. The changes in peripheral blood T lymphocyte subsets and cytokines during RT for pediatric brain tumors and the associati ... Full text Link to item Cite

Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy.

Journal Article Am J Cancer Res · 2021 Recurrence and progression of non-muscle-invasive bladder cancer (NMIBC), frequent despite the availability of multiple treatment modalities, may be partly explained by the presence of immunosuppressive cell populations. We hypothesized that progression of ... Link to item Cite
View All Publications